Sign in
4

Changes in Ownership

Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-20-015766

EVP & Chief Commercial Officer gave up 824 shares (to pay taxes)

  • EVP & Chief Commercial Officer acquired 11,087 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Harris Erik · EVP & Chief Commercial Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2020-03-01 Grant or award : show line 1 in the form +7,800 22,109 D
2020-03-01 Grant or award : show line 2 in the form +3,287 25,396 D
2020-03-01 Shares withheld for taxes : show line 3 in the form −824 $56.08 $46,210 24,572 D

Table II: Derivative

1 line
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2020-03-01 Grant or award : show line 4 in the form Stock Option (Right to Buy) +22,000 $56.08 2030-03-01 22,000 22,000 D
Loading xslF345X03/doc4.xml…